BNTC earnings analysis
What we found in BNTC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Benitec Biopharma did not report any revenue for Q3 2026, yet achieved an improved net loss of $11.9 million, translating to an EPS of $(0.24). This shows a notable recovery from a $14.5 million loss and $(0.38) EPS for the same quarter last year, highlighting effective cost management despite ongoing operational losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved Net Loss and EPS
- Net loss reduced to $11.9 million in Q3 2026 from $14.5 million in Q3 2025, improving EPS from $(0.38) to $(0.24).
- Reduced Total Operating Expenses
- Total operating expenses decreased to $13.6 million from $15.3 million year-over-year, demonstrating enhanced cost control.
- Cash Position Strong
- Cash and cash equivalents improved to $184.8 million as of March 31, 2026, up from $97.7 million at June 30, 2025.
- Ongoing Clinical Development
- BB-301 is in a Phase 1b/2a trial with significant progress, indicating potential future revenue generation.
- Operating Cash Flow Improvement
- Net cash used in operating activities improved to $11.6 million in Q3 2026 from $15.4 million in Q3 2025.
- Increase in Total Stockholders' Equity
- Total stockholders' equity rose to $183.3 million from $97.3 million year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- Management anticipates further operating losses due to ongoing product development and clinical trials.
- Dependence on Clinical Trials
- The success of product candidates like BB-301 relies heavily on clinical trial outcomes, which are uncertain.
- Need for Additional Financing
- Future capital requirements for continued operations and product development have raised concerns regarding further financing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.24
What they said about what is next.
No numeric guidance provided; management discussed future financing needs and continued product development.
The filing reads better than the one before it.
What came before.
- 10-Q · February 12, 2026
- Benitec Biopharma reported no revenue and a continuing net loss for the quarter: net loss of $11,837 thousand (three months ended Dec 31, 2025) and diluted EPS of $(0.26). The company materially strengthened its cash…
- 10-K · September 22, 2025
- Benitec Biopharma is a clinical‑stage company advancing a first‑in‑class ddRNAi “silence and replace” AAV gene therapy (BB‑301) for OPMD. The filing highlights clinical progress (IND cleared June 2023; sixth subject…
- 10-Q · February 13, 2024
- Benitec Biopharma reported zero revenue for the quarter (Licensing revenues $—) and a net loss of $ (6,798) (three months ended December 31, 2023), equivalent to reported EPS of $(2.64). R&D spend rose to $5,102 for the…
- 10-K · September 21, 2023
- Benitec is a clinical-stage genetic medicines company advancing a first-in-class "silence and replace" ddRNAi platform with lead candidate BB-301 for OPMD. The 10-K highlights IND approval to proceed for BB-301 in June…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BNTC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever